New Jersey Trim Clinic

GLP-1 Shaming: Why Treating Obesity Medically Isn't 'Cheating' — It's Science

Published by New Jersey Trim Clinic · Updated 2025-05-07

Using GLP-1 Medication Is Not Cheating — It's Science

There is a growing social trend around GLP-1 medications that has little to do with medicine and everything to do with stigma.

Words like "cheating," "lazy," "the easy way out," and "just eat less" circulate widely online.

At the same time, obesity remains one of the leading contributors to cardiovascular disease, type 2 diabetes, stroke, fatty liver disease, sleep apnea, and reduced life expectancy worldwide.

So let's address this honestly — and clinically.

Obesity Is Not a Willpower Disorder

In 2013, the American Medical Association officially recognized obesity as a disease. The World Health Organization and multiple endocrine societies classify obesity as a chronic, relapsing metabolic condition.

Why does that matter? Because diseases are treated.

We do not tell people with asthma to "breathe harder." We do not tell people with high blood pressure to "relax more." We do not shame someone for using an inhaler or insulin. We treat the biology.

Obesity is driven by hormonal signaling, brain reward pathways, insulin resistance, metabolic adaptation, genetic predisposition, and environmental exposure. Reducing it to "discipline" ignores decades of endocrinology research.

The Biology of Hunger

When someone loses weight, the body does not cooperate. Research from Leibel et al. in the New England Journal of Medicine demonstrated that after weight loss, resting metabolic rate decreases, energy efficiency increases, hunger hormones rise, and satiety hormones fall.

This is called metabolic adaptation.

In practical terms, the body fights weight loss. Ghrelin (the hunger hormone) increases. Leptin (the fullness hormone) decreases. Food becomes more rewarding neurologically.

This is not weakness. It is physiology.

For many individuals with moderate to severe obesity, this adaptive response makes sustained 15-20% weight loss through lifestyle alone biologically difficult. That reality is not moral. It is scientific.

What GLP-1 Medications Actually Do

GLP-1 receptor agonists mimic a natural gut hormone that regulates appetite and insulin response. They slow gastric emptying, increase insulin secretion in response to glucose, suppress glucagon, reduce central appetite signaling, and decrease reward activation in response to high-calorie foods.

In clinical trials, semaglutide produced approximately 15% average weight loss (STEP-1, NEJM 2021). Tirzepatide produced up to 20% average weight loss (SURMOUNT-1, NEJM 2022). These are outcomes previously seen primarily with bariatric surgery.

This is not cosmetic weight loss. This is metabolic treatment.

Why the "Easy Way Out" Argument Falls Apart

No one describes chemotherapy as "the easy way out." No one calls statins "cheating." No one accuses someone of laziness for using CPAP for sleep apnea.

But obesity has been culturally moralized.

GLP-1 therapy does not eliminate effort. Patients still modify diet, improve protein intake, increase resistance training, monitor behaviors, and manage sleep. The medication regulates appetite. It does not remove responsibility. It removes the constant biological headwind.

The Courage Factor

For many individuals, starting GLP-1 therapy is not vanity-driven. It is health-driven.

The SELECT trial (2023) showed that semaglutide reduced major adverse cardiovascular events in individuals with overweight or obesity without diabetes. That is not cosmetic benefit. That is morbidity reduction.

Choosing treatment to reduce heart attack risk is not weakness. It is proactive healthcare.

Why Shaming Is Clinically Counterproductive

Weight stigma itself is associated with increased stress hormones, emotional eating, avoidance of medical care, and higher long-term weight gain.

Stigma does not improve health outcomes. It worsens them. When patients are shamed, they delay treatment. When patients are supported, they engage.

The Balanced Truth

GLP-1 medications are not for everyone. They require medical supervision. They have side effects. They require long-term planning.

But using evidence-based treatment for a recognized chronic disease is not cheating. It is informed healthcare.

If we normalize insulin for diabetes, inhalers for asthma, and statins for cholesterol, we can normalize medically supervised obesity treatment.

The goal is not appearance. The goal is metabolic health, longevity, and quality of life. And seeking that is not weakness. It is strength.

New Jersey Patients: You Deserve Support, Not Judgment

At New Jersey Trim Clinic, we do not judge. We treat. Physician-supervised GLP-1 programs via telehealth — $149/month, all-inclusive, no membership fees. Whether you are in Bergen County, Camden, Trenton, or the Shore, you can start your journey from home.

Read more about GLP-1 science and patient advocacy at our Patient Education Library: www.eliminatethefoodnoiseinyourhead.com

*This article is adapted from our Patient Education Library. Original article: "GLP-1 Shaming: Why Treating Obesity Medically Isn't 'Cheating' — It's Science." References include the American Medical Association (2013), Leibel et al. (NEJM 1995), van Bloemendaal et al. (Diabetes 2014), Wilding et al. (NEJM 2021), Jastreboff et al. (NEJM 2022), and the SELECT Trial Investigators (NEJM 2023).*

*Individual results vary. Treatment is only prescribed after evaluation by a licensed medical provider. No specific amount of weight loss is guaranteed.*

MEDICAL SOURCES & FURTHER READING

Read the source alongside the specific topic it supports. These independent sources do not endorse New Jersey Trim Clinic. Research findings are not a prediction of your results.

  • NIH/NIDDK — Prescription Medications to Treat Overweight & Obesity

    Supports: Weight-management medication requires individualized prescribing; eligibility, benefits, risks and ongoing treatment should be discussed with a healthcare professional. Nutrition and physical activity remain part of treatment.

  • Mayo Clinic — Prescription weight-loss drugs

    Supports: Prescription weight-loss medicines have eligibility restrictions, potential side effects and a need for professional oversight; they are used alongside lifestyle measures.

  • Cleveland Clinic — GLP-1 Agonists

    Supports: GLP-1 receptor agonists act on appetite and satiety, help regulate blood glucose and can slow stomach emptying. Common adverse effects include nausea, vomiting and diarrhea.

    Evidence limits: The extent and duration of effects differ by drug, dose and individual; a general mechanism does not establish a guaranteed response.

  • Once-Weekly Semaglutide in Adults with Overweight or Obesity

    Supports: Semaglutide 2.4 mg plus lifestyle intervention produced weight loss in the STEP 1 randomized trial; gastrointestinal adverse events were reported.

    Evidence limits: The main trial reported mean weight change of −14.9% at 68 weeks. This is not a predicted clinic outcome or proof that every semaglutide formulation has the same results.

  • FDA — Wegovy (semaglutide) prescribing information

    Supports: The approved product's label describes contraindications including personal or family history of medullary thyroid carcinoma and MEN 2, dose escalation, pregnancy considerations, gastrointestinal reactions, and warnings including pancreatitis, gallbladder disease and kidney injury due to volume depletion.

    Evidence limits: This label is for Wegovy, not approval of New Jersey Trim Clinic or a compounded formulation. Individual prescribing decisions require a licensed provider.

  • Tirzepatide Once Weekly for the Treatment of Obesity

    Supports: The SURMOUNT-1 trial studied tirzepatide at different doses in adults with obesity or overweight without diabetes and reported weight reduction and gastrointestinal adverse events.

    Evidence limits: SURMOUNT-1 was placebo-controlled, not a head-to-head comparison with semaglutide. Results do not establish guaranteed outcomes or equivalence of compounded medicines.

  • The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity

    Supports: A randomized study reported reduced hunger, food cravings and energy intake, and improved control of eating with semaglutide.

    Evidence limits: This study does not establish a diagnosis of 'food noise', prove that all intrusive food thoughts have one cause, or show that every patient will experience relief. It found no evidence of delayed gastric emptying at week 20 using its indirect test.

  • Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

    Supports: Weight regain was observed after withdrawal of semaglutide and lifestyle intervention in the exploratory STEP 1 extension.

    Evidence limits: The extension involved a subset of trial participants; it does not establish that every patient needs lifelong medication.

  • NIH/NIDDK — Factors Affecting Weight & Health

    Supports: Weight is influenced by lifestyle, sleep, medicines, health conditions, family history and other factors; insufficient sleep can affect hunger.

    Evidence limits: This general guidance does not establish the cause of an individual patient's cravings, emotional eating, insulin resistance or weight changes.

  • FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

    Supports: Compounded GLP-1 drugs are not FDA-approved. FDA describes dosing, quality, storage and other safety concerns, and advises that compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug.

    Evidence limits: Pharmacy registration is not FDA approval of a compounded product. Clinical trials of approved drugs do not establish the safety or effectiveness of compounded formulations.

RESEARCH & REFERENCES

General education is not individualized medical advice. Prescription treatment requires evaluation by a licensed provider. Eligibility, medication and dosing depend on individual circumstances.

Compounded drugs are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before marketing. Compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug. Published studies of approved medications do not establish equivalent safety or effectiveness of compounded products.

Browse more New Jersey Trim Clinic patient education.